HUMAN MEDICINES EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR): RITEMVIA, RITUXIMAB, LYMPHOMA, NON-HODGKIN,MICROSCOPIC POLYANGIITIS,WEGENER GRANULOMATOSIS, DATE OF AUTHORISATION: 13/07/2017, REVISION: 8, STATUS: AUTHORISED
(AGENPARL) – LONDON (UNITED KINGDOM), gio 11 febbraio 2021 Ritemvia is a medicine used to treat the following blood cancers and inflammatory conditions: follicular lymphoma and diffuse large B cell non-Hodgkin’s lymphoma (two types of non-Hodgkin’s lymphoma, a blood cancer); granulomatosis with polyangiitis (GPA or Wegener’s granulomatosis) and microscopic polyangiitis......